Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Research
Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Articles

Leukemia of Short Latency in Mice Injected with Human Malignant Tissue by Intrasplenic Route

Christiane Dosne de Pasqualini, A. Pavlovsky, C. Vasquez, E. A. D. Holmberg and S. L. Rabasa
Christiane Dosne de Pasqualini
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. Pavlovsky
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C. Vasquez
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
E. A. D. Holmberg
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S. L. Rabasa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published May 1965
  • Article
  • Info & Metrics
  • PDF
Loading

Summary

Biopsy and/or bone-marrow specimens from human neoplasias were injected, by means of a trocar, into the spleen of 20 young adult BALB mice (I1). Ten days later, the granulomatous tissue at the site of injection was loaded into a trocar and deposited into the spleen of a 2nd group of 10–20 mice (I2a); the remaining portions of the spleens were homogenized and inoculated i.p. into a 3rd group of 10–20 mice (I2b). Again 10 days later, the spleens of mice from group I2a were homogenized and administered i.p. to a 4th group of 10–20 mice (I3).

Two cases of stem-cell sarcoma and 1 case of fibrosarcoma gave the following results: in Case 1, 10 of 22 (45%), and in Case 2, all of 10 mice (100%), from the I2b groups, developed leukemia 40 and 19 days, respectively, after they were injected (and 50 and 29 days, respectively, after the original injection I1); in Case 3, 15 of 17 mice (88%) from Group I3 became leukemic 32 days after they were injected (and 52 days after the original injection I1). In Case 3, these results were confirmed using bone marrow, yielding 4 leukemias in 8 members of the same I3 group. Cellular transplantation of the leukemias originating from these 3 cases are being carried in serial form.

Both the original and transplanted leukemias were examined under the electron microscope, revealing the presence of A1 and C viral particles.

These 3 cases are part of a series including 31 human malignancies, mainly lymphomas, with 8 tonsils, 6 muscles, and 3 normal bone marrows as controls. In all but the 3 above-mentioned cases, no leukemias were observed within the same period of time.

No explanation of this phenomenon can be advanced but 3 working hypotheses are submitted.

Footnotes

  • ↵2 Partly supported by FUNDALEU (fundacion para combatir la leucemia).

  • Received August 4, 1964.
  • Revision received January 8, 1965.
  • ©1965 American Association for Cancer Research.
PreviousNext
Back to top
May 1965
Volume 25, Issue 4 Part 1
  • Table of Contents
  • Table of Contents (PDF)
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)

Sign up for alerts

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Leukemia of Short Latency in Mice Injected with Human Malignant Tissue by Intrasplenic Route
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Leukemia of Short Latency in Mice Injected with Human Malignant Tissue by Intrasplenic Route
Christiane Dosne de Pasqualini, A. Pavlovsky, C. Vasquez, E. A. D. Holmberg and S. L. Rabasa
Cancer Res May 1 1965 (25) (4 Part 1) 565-573;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Leukemia of Short Latency in Mice Injected with Human Malignant Tissue by Intrasplenic Route
Christiane Dosne de Pasqualini, A. Pavlovsky, C. Vasquez, E. A. D. Holmberg and S. L. Rabasa
Cancer Res May 1 1965 (25) (4 Part 1) 565-573;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • BRCA1, BRCA2, and Rad51 Operate in a Common DNA Damage Response Pathway
  • Introduction of H. Robert Horvitz
  • Membership of Selection Committees
Show more Articles
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement